Search
Reveal®

Rapid HIV-1/2

antibody test

Accurate, rapid detection of HIV antibodies in whole blood, plasma, or serum – trusted worldwide for reliable diagnosis in just three simple steps.

Answers in real time

Reveal® G4 Rapid HIV-1/2 Antibody Test enables fast and accurate detection of HIV-1 and HIV-2 antibodies using MedMira’s patented Rapid Vertical Flow (RVF) Technology™. FDA approved and CDC validated, it provides instant results in a straightforward three-step process and is available in different formats suitable for laboratory and point-of-care use. Its proven performance supports reliable testing and timely clinical and public health decision-making.

  • Immediate results

    No waiting time, results do not vanish.

  • Reliable accuracy

    Achieves high HIV-1/2 testing performance across multiple specimen matrices.

  • No equipment or refrigeration required

    Stores at room temperature (2–30 °C / 35–86 °F) with an 18-month shelf life.

  • Easy to use and interpret

    Simple procedure with instant, easy-to-read results, no special training required.

  • Ideal for any setting

    Works with serum, plasma, and whole blood (venipuncture or fingerstick).

  • External test controls

    Provides an easy-to-use method for lot release and quality assurance.

g4 rapid test
From sample to results

in three simple Steps

Testing doesn’t have to be complicated. Our intuitive three-step process ensures instant, consistent results with minimal effort.

add buffer from v2 to blue cap
Pour buffer

Pour buffer onto the InstantGold™ cap.

c t add blue cap on cartridge scale
Cap

Place the InstantGold™ cap on the cartridge.

c t add blood on cartridge
Add sample

Pour lysed blood specimen into the test cartridge.

Watch this video (YouTube, 1:47 min) for a quick overview,
or view the full training video here for more detailed guidance (Youtube, 3:47 min).

add buffer to blue cap scale
Cap & Pour buffer

Place InstantGold™ cap on the test & 
add buffer.

c t add serum plasma using pipette scale
Add specimen

Apply specimen to the centre of the test membrane.

c t add buffer on cartridge scale
Pour buffer

Apply buffer to the test center.

For a detailed walkthrough, watch video (Youtube, 2:19 min)

Proven Results, Trusted Performance

Testing whole blood specimens with Reveal® G4 Rapid HIV-1/2 Antibody Test provides a higher degree of accuracy than some traditional, more time-consuming laboratory tests.
99.64
HIV-1 Sensitivity (PPA)
99.71
HIV-1 Specificity (NPA)
100
HIV-2 Sensitivity (PPA)
100
HIV-2 Specificity (NPA)

Our test tailored to your needs

The Reveal® G4 Rapid HIV-1/2 Antibody Test is trusted in the U.S. for both point-of-care and laboratory settings. Working with regional distribution partners, we provide broad access to three formats designed for different testing environments and offer laboratory test controls to ensure consistent performance.

Point-of-Care

This format includes a test tray in each pouch and is ideally suited to testing at the point of patient care, settings such as mobile clinics requiring a portable and all-in-one testing solution.

  • Cat. No. 815311007583
  • Qty. 20 tests per box
LAB+

The LAB+ format is designed for laboratory use, offering maximum flexibility for testing serum, plasma, and venipuncture whole blood with reliable and consistent results.

  • Cat. No. 815311007576
  • Qty. 50 tests per box
LAB S/P

The LAB S/P format is designed for laboratory use, ideally suited for serum and plasma specimens and batch testing, ensuring efficient processing and dependable performance.

  • Cat. No. 815311000591
  • Qty. 50 tests per box
Test control

HIV-1/2 Antibody test controls are designed for use in customer quality assurance practices, stored at room temperature until ready for use. Each vial is sufficient to perform five Reveal® G4 tests. For step-by-step instructions, please watch our procedure video (Youtube, 6:58)

  • Cat. No. 815311007590
  • Qty. 1 HIV-1 Positive, 1 HIV-2 Positive, 1 HIV-1/2 Negative Test Control, 1 vial of reconstitution Buffer and 15 pipettes
tp pou components
reveal g4 labplus
reveal g4 labsp
reveal hiv 1 2 test control

Downloads and Links

Additional materials are available through your partner login or upon request.

Related Products

Miriad is intended for laboratory, academic, and research use only, and is not for use in diagnostic procedures.

Learn more about our upcoming technology and products advancing through our development pipeline.

Frequently Asked Questions

To learn more about Reveal® G4 Rapid HIV-1/2 Antibody Test, please contact us.

What is RVF technology™?

RVF (Rapid Vertical Flow) is a flow-through technology that captures specific biomarkers from blood, serum, or plasma samples on a specialized membrane, delivering instant visual results.
Learn more

How accurate is Reveal® G4 Rapid HIV-1/2 Antibody Test?

In serum and plasma, Reveal® G4 Rapid HIV-1/2 Antibody Test demonstrates 99.8% sensitivity for HIV-1 antibodies and 100% sensitivity for HIV-2 antibodies, with a specificity of 98.6% in plasma and 99.1% in serum. In fingerstick whole blood, the test provides 99.64% sensitivity for HIV-1 antibodies and 100% sensitivity for HIV-2 antibodies, along with a specificity of 99.71%.

Where to buy Reveal® G4 Rapid HIV-1/2 Antibody Test?

You can purchase our products through authorized distributors in your region. Visit our ‘Partner’ page or contact our team for purchasing information in your region. For more information, contact sales@medmira.com.

Partners

Contact Us

What is HIV-1 and HIV-2?

HIV-1 and HIV-2 are two types of the human immunodeficiency virus that weaken the immune system over time, leading to acquired immunodeficiency syndrome (AIDS) and related complications. HIV-1 is far more prevalent within North America and most regions worldwide. HIV-2 is primarily found in West Africa with increased cases recognized in other regions. HIV-2 typically progresses more slowly than HIV-1. Reveal® G4 Rapid HIV-1/2 Antibody Test detects antibodies to both HIV-1 and HIV-2, ensuring accurate and comprehensive results.

What makes Reveal® G4 Rapid HIV-1/2 Antibody Test different?

Reveal® G4 Rapid HIV-1/2 Antibody Test uses MedMira’s unique Rapid Vertical Flow (RVF) technology, which delivers results in under three minutes – significantly faster than conventional lateral flow assays. The RVF format requires only one buffer and features a single reaction window, reducing user steps and minimizing error potential. Unlike traditional tests that depend on strict timing or multiple wash steps, RVF provides timeless, easy-to-read results with no refrigeration or specialized equipment required. The technology offers laboratory-grade accuracy, low cost per test, and supports multiplexing for future assay expansion – combining speed, simplicity, and performance in a single platform.

Answers in real time

Reveal® G4 Rapid HIV-1/2 Antibody Test enables fast and accurate detection of HIV-1 and HIV-2 antibodies using MedMira’s patented Rapid Vertical Flow (RVF) Technology™. Health Canada approved, it provides instant results in a straightforward three-step process and is available in different formats suitable for laboratory and point-of-care use. Its proven performance supports reliable testing and timely clinical and public health decision-making.

  • Immediate results

    No waiting time, results do not vanish.

  • Reliable accuracy

    Achieves high HIV-1/2 testing performance across multiple specimen matrices.

  • No equipment or refrigeration required

    Stores at room temperature (2–30 °C / 35–86 °F) with an 12-month shelf life.

  • Easy to use and interpret

    Simple procedure with instant, easy-to-read results, no special training required.

  • Ideal for any setting

    Works with serum, plasma, and whole blood (venipuncture or fingerstick).

  • External test controls

    Provides an easy-to-use method for lot release and quality assurance.

g4 rapid test
From sample to results

in three simple Steps

Testing doesn’t have to be complicated. Our intuitive three-step process ensures instant, consistent results with minimal effort.

add buffer from v2 to blue cap
Pour buffer

Pour buffer onto the InstantGold™ cap.

c t add blue cap on cartridge scale
Cap

Place the InstantGold™ cap on the cartridge.

c t add blood on cartridge
Add sample

Pour lysed blood specimen into the test cartridge.

Watch this video (YouTube, 1:47 min) for a quick overview,
or view the full training video here for more detailed guidance (Youtube, 3:47 min).

add buffer to blue cap scale
Cap & Pour buffer

Place InstantGold™ cap on the test &
 add buffer.

c t add serum plasma using pipette scale
Add specimen

Apply specimen to the centre of the test membrane.

c t add buffer on cartridge scale
Pour buffer

Apply buffer to the test center.

For a detailed walkthrough, watch video (Youtube, 6:33 min)

Proven Results, Trusted Performance

Testing whole blood specimens with Reveal® G4 Rapid HIV-1/2 Antibody Test provides a higher degree of accuracy than some traditional, more time-consuming laboratory tests.
99.64
HIV-1 Sensitivity (PPA)
99.71
HIV-1 Specificity (NPA)
100
HIV-2 Sensitivity (PPA)
100
HIV-2 Specificity (NPA)

Our test tailored to your needs

Our single HIV-1/2 antibody test is trusted in Canada for both point-of-care and laboratory settings. Working with regional distribution partners, we provide broad access to two formats designed for different testing environments and offer laboratory test controls to ensure consistent performance.

Point-of-Care
g4 rapid test
LAB S/P
HIV EU

Related Products

Designed for use across POC settings, laboratories, academic institutions, and research environments.

Designed for use across POC settings, laboratories, academic institutions, and research environments.

Miriad is intended for laboratory, academic, and research use only, and is not for use in diagnostic procedures.

Learn more about our upcoming technology and products advancing through our development pipeline.

Frequently Asked Questions

To learn more about Reveal® G4 Rapid HIV-1/2 Antibody Test, please contact us.

What is RVF technology™?

RVF (Rapid Vertical Flow) is a flow-through technology that captures specific biomarkers from blood, serum, or plasma samples on a specialized membrane, delivering instant visual results.
Learn more

How accurate is Reveal® G4 Rapid HIV-1/2 Antibody Test?

In serum and plasma, Reveal® G4 Rapid HIV-1/2 Antibody Test demonstrates 99.8% sensitivity for HIV-1 antibodies and 100% sensitivity for HIV-2 antibodies, with a specificity of 98.6% in plasma and 99.1% in serum. In fingerstick whole blood, the test provides 99.64% sensitivity for HIV-1 antibodies and 100% sensitivity for HIV-2 antibodies, along with a specificity of 99.71%.

Where to buy Reveal® G4 Rapid HIV-1/2 Antibody Test?

You can purchase our products through authorized distributors in your region. Visit our ‘Partner’ page or contact our team for purchasing information in your region. For more information, contact sales@medmira.com.
Partners
Contact us

What is HIV-1 and HIV-2?

HIV-1 and HIV-2 are two types of the human immunodeficiency virus that weaken the immune system over time, leading to acquired immunodeficiency syndrome (AIDS) and related complications. HIV-1 is far more prevalent within North America and most regions worldwide. HIV-2 is primarily found in West Africa with increased cases recognized in other regions. HIV-2 typically progresses more slowly than HIV-1. Reveal® G4 Rapid HIV-1/2 Antibody Test detects antibodies to both HIV-1 and HIV-2, ensuring accurate and comprehensive results.

What makes Reveal® G4 Rapid HIV-1/2 Antibody Test different?

Reveal® G4 Rapid HIV-1/2 Antibody Test uses MedMira’s unique Rapid Vertical Flow (RVF) technology, which delivers results in under three minutes – significantly faster than conventional lateral flow assays. The RVF format requires only one buffer and features a single reaction window, reducing user steps and minimizing error potential. Unlike traditional tests that depend on strict timing or multiple wash steps, RVF provides timeless, easy-to-read results with no refrigeration or specialized equipment required. The technology offers laboratory-grade accuracy, low cost per test, and supports multiplexing for future assay expansion – combining speed, simplicity, and performance in a single platform.

Current Product Information for the EU

The Reveal® Rapid HIV Test is currently not authorized for diagnostic use in the EU and is limited to non-diagnostic applications in CE-regulated markets.

Research Use Only Alternatives

For customers in the EU who require products for research applications, we recommend our Miriad® Research Use Only (RUO) product line. Please refer to the Miriad® RUO product pages for further details, and specifications.

miriad

Explore your options with us

If you have any questions regarding Reveal® Rapid HIV Test, its regulatory status in the EU, or suitable research alternatives, please contact us for further information.
International

Outside North America, and the EU

Answers in real time

Reveal® Rapid HIV Antibody Test enables fast and accurate detection of HIV-1 and HIV-2 antibodies using MedMira’s patented Rapid Vertical Flow (RVF) Technology™. It provides instant results in a straightforward three-step process and is available in different formats suitable for laboratory and point-of-care use. Its proven performance supports reliable testing and timely clinical and public health decision-making.
  • Immediate results

    No waiting time, results do not vanish.

  • Reliable accuracy

    Achieves high HIV-1/2 testing performance across multiple specimen matrices.

  • No equipment or refrigeration required

    Stores at room temperature (2–30 °C / 35–86 °F) with a 12-month shelf life.

  • Easy to use and interpret

    Simple procedure with instant, easy-to-read results, no special training required.

  • Ideal for any setting

    Works with serum, plasma, and whole blood (venipuncture or fingerstick).

HIV EU
From sample to results

in three simple Steps

Testing doesn’t have to be complicated. Our intuitive three-step process ensures instant, consistent results with minimal effort.

add buffer from v2 to blue cap
Pour buffer

Pour buffer onto the InstantGold™ cap.

c t add blue cap on cartridge scale
Cap

Place the InstantGold™ cap on the cartridge.

c t add blood on cartridge
Add sample

Pour lysed blood specimen into the test cartridge.

Watch this video (YouTube, 1:47 min) for a quick overview,
or view the full training video here for more detailed guidance (Youtube, 3:47 min).

add buffer to blue cap scale
Cap & Pour buffer

Place InstantGold™ cap on the test & 
add buffer.

c t add serum plasma using pipette scale
Add specimen

Apply specimen to the centre of the test membrane.

c t add buffer on cartridge scale
Pour buffer

Apply buffer to the test center.

For a detailed walkthrough, watch video (Youtube, 2:19 min)

Proven Results, Trusted Performance

Testing whole blood specimens with Reveal® G4 Rapid HIV-1/2 Antibody Test provides a higher degree of accuracy than some traditional, more time-consuming laboratory tests.
99.64
HIV-1 Sensitivity (PPA)
99.71
HIV-1 Specificity (NPA)
100
HIV-2 Sensitivity (PPA)
100
HIV-2 Specificity (NPA)

Our test tailored to your needs

The Reveal® Rapid HIV Antibody Test is trusted worldwide for both point-of-care and laboratory settings. Working with regional distribution partners, we provide broad access to three formats designed for different testing environments.

Point-of-Care

This format includes a test tray in each pouch and is ideally suited to testing at the point of patient care, settings such as mobile clinics requiring a portable and all-in-one testing solution.

  • Qty. 20 tests per box
LAB+

The LAB+ format is designed for laboratory use, offering maximum flexibility for testing serum, plasma, and venipuncture whole blood with reliable and consistent results.

  • Qty. 50 tests per box
LAB S/P

The LAB S/P format is designed for laboratory use, ideally suited for serum and plasma specimens and batch testing, ensuring efficient processing and dependable performance.

  • Qty. 50 tests per box
tp pou components
reveal g4 labplus
reveal g4 labsp

Related Products

Designed for use across POC settings, laboratories, academic institutions, and research environments.

Designed for use across POC settings, laboratories, academic institutions, and research environments.

Miriad is intended for laboratory, academic, and research use only, and is not for use in diagnostic procedures.

Learn more about our upcoming technology and products advancing through our development pipeline.

Frequently Asked Questions

To learn more about Reveal® Rapid HIV Antibody Test, please contact us.

What is RVF technology™?
RVF (Rapid Vertical Flow) is a flow-through technology that captures specific biomarkers from blood, serum, or plasma samples on a specialized membrane, delivering instant visual results.
Learn more
How accurate is Reveal® G4 Rapid HIV-1/2 Antibody Test?

In serum and plasma, Reveal® Rapid HIV Antibody Test demonstrates 99.8% sensitivity for HIV-1 antibodies and 100% sensitivity for HIV-2 antibodies, with a specificity of 98.6% in plasma and 99.1% in serum. In fingerstick whole blood, the test provides 99.64% sensitivity for HIV-1 antibodies and 100% sensitivity for HIV-2 antibodies, along with a specificity of 99.71%.

Where to buy Reveal® G4 Rapid HIV-1/2 Antibody Test?
You can purchase our products through authorized distributors in your region. Visit our ‘Partner’ page or contact our team for purchasing information in your region. For more information, contact sales@medmira.com.
Partners Contact Us
What is HIV-1 and HIV-2?

HIV-1 and HIV-2 are two types of the human immunodeficiency virus that weaken the immune system over time, leading to acquired immunodeficiency syndrome (AIDS) and related complications. HIV-1 is the most common strain globally, while HIV-2 typically progresses more slowly. Reveal® Rapid HIV Antibody Test detects antibodies to both, ensuring accurate and comprehensive results.

What makes Reveal® G4 Rapid HIV-1/2 Antibody Test different?

Our Reveal® Rapid HIV Antibody Test test uses MedMira’s unique Rapid Vertical Flow (RVF) technology, which delivers instant results – significantly faster than conventional lateral flow assays. The RVF format requires only one buffer and features a single reaction window, reducing user steps and minimizing error potential. Unlike traditional tests that depend on strict timing or multiple wash steps, RVF provides timeless, easy-to-read results with no refrigeration or specialized equipment required. The technology offers laboratory-grade accuracy, low cost per test, and supports multiplexing for future assay expansion – combining speed, simplicity, and performance in a single platform.

Privacy Policy

Last updated: April 20, 2026

MedMira Inc. (“MedMira”, “we”, “us”, or “our”) is committed to protecting personal information in accordance with applicable privacy laws, including the Personal Information Protection and Electronic Documents Act (PIPEDA) in Canada, as well as applicable United States and international privacy requirements.

This Privacy Policy describes how we collect, use, disclose, and safeguard personal information through our website. Our website is primarily informational in nature and does not provide user accounts, applications, or diagnostic services.

Terms And Conditions Of Use

Please Read These Terms Carefully Before Using This Site. This website is provided by MedMira Inc. (MedMira) and may be used for informational purposes only. By using the site or downloading materials from the site, you agree to abide by the terms and conditions set forth in this notice. If you do not agree to abide by these terms and conditions do not use the site or download materials from the site.

Subscribe
Join our newsletter

Receive company updates, regulatory milestones, and event announcements.

By subscribing, you agree to our Privacy Policy and consent to receive updates.

Committed to quality
Certified & Proven Quality

Our quality management system is ISO 13485:2016 certified, compliant with the United States Food and Drug Administration’s current Good Manufacturing Practices (cGMP: Quality System Regulation Part 820 of CFR Title 21, Volume 8), European Union’s Directive 98/79/EC on in vitro diagnostic medical devices, and Health Canada Medical Device Regulations (SOR/98-282).

Additionally, we adhere to ISO 14971 (Application of Risk Management to Medical Devices) and ISO 2859 (Sampling Procedures for Inspection by Attributes). Certification and compliance to these requirements attests to our ability to maintain the highest standard of quality in medical device manufacturing, product development and corporate conduct.

Our products have been approved by regulators and UN agencies worldwide.

FDA

Health Canada

International Trade Centre (ITC)

Pan American Healtch Organization (PAHO)

UN Development Programme (UNDP)

UN Office for Project Services (UNOPS)

UN Office at Vienna (UNOV)

UN Population Fund (UNFPA)

United States Agency for International Development (USAID)

CFO & Head of Commercialization

Markus Meile

Markus joined MedMira in 2010, and moved into the role of Chief Financial Officer in 2014.

He previously served on the Company’s Board of Directors, as a member of the Audit Committee, and as the Senior Director of International Markets.

Prior to joining MedMira, Markus worked with a number of financial institutions in Switzerland, England, and Hong Kong. He holds a BSc from Royal Holloway University of London and has studied business management, strategic planning, investment and accounting at business school in Zurich. Previously, Markus worked in the medical device industry in Africa, Asia Pacific, and Europe.

He will combine his financial expertise with his broad range of international business knowledge to build financial and corporate strategies supporting MedMira’s continuing growth and increasing shareholder value.

Director of the Audit Committee, Nomination and Compensation Committee

Jianhe Mao

Jianhe Mao is the owner of Unipec, a consulting firm based in St. Gallen, Switzerland. Unipec focuses on helping European companies enter the Chinese market, through operational restructuring and ownership and management optimization.

In addition to leading Unipec, Mr. Mao is involved in several industrial projects and start-up ventures including Monsatec AG, a new company bridging the gap between laboratories and clinics with a cold plasma medical device. He serves on the boards of several European companies and is regarded as a trusted expert in legal cases, corporate corruption, operational turnarounds, and mergers and acquisitions.

Mr. Mao began his career as a project engineer and has gained experience in business development and real estate investment. He holds M.E. from Ruhr University Bochum.

CEO, Co-Founder & Co-Inventor

Hermes Chan, D.Sc. (h.c.)

Hermes Chan, our Chief Executive Officer and Co-Founder, leads our passionate and committed team in driving the strategic direction and growth of MedMira.

Hermes, who was named BioScience Innovator of the Year by The Economist in 2007, is the inventor of our patented rapid flow-through diagnostic technology platform.

Since the company’s inception in 1994 Hermes has held progressively senior management roles including Research Scientist, General Manager, Senior Vice President, and Chief Operating Officer.

Prior to creating MedMira, Hermes worked with another Canadian biotechnology company in the diagnostics research sector.

Chair member of the Audit Committee, Nomination and Compensation Committee

Steven Cummings

Mr. Steven Cummings is the Founder & President of Cambridge Financial Services, one of the leading full service accounting, tax, and business advisory firms in Nova Scotia.

Under Mr. Cummings leadership, Cambridge Financial has earned an enviable reputation among businesses and industry for a commitment to high standards. Along with his leadership responsibilities at Cambridge Financial Services, Mr. Cummings was engaged as MedMira’s interim Chief Financial Officer in 2007.

With more than 30 years of financial and entrepreneurial experience, Mr. Cummings is a frequent guest speaker on issues surrounding provincial taxation, taxation of seniors, and business ownership

Intellectual property

China

ZL02819646.5

Rapid Diagnostic Device and Assay

Intellectual property

European union

EP1417489

Rapid Diagnostic Device and Assay

EP1328811

HCV Mosaic Antigen Composition (2021)

Intellectual property

USA

9,164,087

Rapid Diagnostic Device, assay and multifunctional Buffer

9,086,410

Downward or vertical flow diagnostic device and assay

8,025,850

Rapid Diagnostic Device, Assay and Multifunctional Buffer

8,287,817

Rapid Diagnostic Device, Assay and Multifunctional Buffer

8,586,375

Rapid Diagnostic Device, Assay and Multifunctional Buffer

7,531,362

Rapid Diagnostic Device, Assay and Multifunctional Buffer

D706945

Diagnostic Device

D706466

Diagnostic Device

11,353,450

Analyte Detection Using Raman Spectroscopy

Intellectual property

Canada

CA2,493,616

Rapid Diagnostic Device, Assay and Multifunctional Buffer

CA2,740,902

Downward or Vertical Flow Diagnostic Device and Assay

CA2,949,634

Analyte Detection Using Raman Spectroscopy

MiROQ Vision

Handheld Device

A future concept built on the same MIROQ technology, designed to deliver lab-grade precision in the palm of your hand.

We envision a future where testing can happen anywhere, anytime – from hospitals and clinics to remote regions or even at home – enabling early disease detection and turning knowledge into real impact. No large equipment or complex infrastructure required.

For: Doctor’s offices, small and mobile clinics

Future application: Home use

Connectivity: Bluetooth, Wifi and USB